Latest Research Development News

Entropy Neurodynamics has received a $1.73 million R&D tax incentive refund from the Australian Government, reinforcing its clinical development of an intravenous psilocin treatment for neuropsychiatric disorders.

ClearVue Technologies has locked in a $3 million structured funding facility tied to its R&D tax credits, aiming to accelerate certification milestones and commercial deployment without diluting shareholders.

BetMakers Technology Group Ltd reported an 11.4% rise in half-year revenue to $46.1 million alongside a dramatic 80% reduction in losses, setting the stage for accelerated global growth and a strategic US market push.

Advanced Braking Technology Ltd reported a robust 27.2% revenue increase and a 61.6% rise in net profit for H1 2026, driven by strong international sales and progress in autonomous braking technology.

Barton Gold Holdings has distributed over $640,000 in Junior Minerals Exploration Incentive tax credits to investors from its June 2025 placement, enhancing returns amid strong exploration activity.

Terragen Holdings reports a 23% reduction in half-year net loss amid strategic shifts and completes a $7 million equity raise to accelerate global commercialisation of its biological agricultural products.

Cycliq Group Limited reported a 27% revenue decline for the half-year ending December 2025 but managed to return to profitability amid strategic platform upgrades and steady customer engagement.

Careteq Limited reported a disciplined operating cash flow in Q2 FY26 with strong growth in its Embedded Health Solutions segment and ongoing resolution of an ATO tax incentive dispute.

IODM Limited has reported a standout Q2 FY26 with record cash receipts driven by strong UK education sector growth and strategic board renewal.

Cycliq Group Ltd reported a 21% decline in customer receipts for Q2 FY2026, offset by a solid net operating cash inflow and a strong Black Friday campaign that generated $1.3 million in gross revenue.

Echo IQ has completed clinical validation of its EchoSolv HF heart failure detection software with the Mayo Clinic Platform, achieving outstanding accuracy. The company has now formally submitted its FDA 510(k) clearance application, positioning itself for significant commercial expansion in the US healthcare market.

Genetic Signatures reported a $3.3 million quarterly revenue with growing international sales and a robust cash position, while preparing for a leadership change.